Diagnostic Performances of PET/CT Using Fibroblast Activation Protein Inhibitors in Patients with Primary and Metastatic Liver Tumors: A Comprehensive Literature Review DOI Open Access

Federica Manuppella,

Giusi Pisano, Silvia Taralli

et al.

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(13), P. 7197 - 7197

Published: June 29, 2024

PET/CT using radiolabeled fibroblast activation protein inhibitors (FAPIs) is a promising diagnostic tool in oncology, especially when non-increased and/or physiologically high [18F]FDG uptake (as liver parenchyma) observed. We aimed to review the role of FAPIs primary metastatic lesions, and compare their performances with more "conventional" radiopharmaceuticals. A search algorithm based on terms "FAPI" AND ("hepatic" OR "liver") was applied, last update 1st January 2024. Out 177 articles retrieved, 76 studies reporting application FAPI at least one patient harboring or lesion(s) were fully analyzed. Although there some heterogeneity clinical conditions study methodology, showed an excellent performance common malignancies (hepatocarcinoma, intrahepatic cholangiocarcinoma) metastases (mostly from gastrointestinal tract lungs). higher tumor-to-background ratio for than found due lower background activity. Despite limited evidence, may be used assess suitability effectiveness FAPI-derived therapeutic agents such as [177Lu]Lu-FAPI. However, future prospective research wider population needed confirm performance.

Language: Английский

Diagnostic Performances of PET/CT Using Fibroblast Activation Protein Inhibitors in Patients with Primary and Metastatic Liver Tumors: A Comprehensive Literature Review DOI Open Access

Federica Manuppella,

Giusi Pisano, Silvia Taralli

et al.

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(13), P. 7197 - 7197

Published: June 29, 2024

PET/CT using radiolabeled fibroblast activation protein inhibitors (FAPIs) is a promising diagnostic tool in oncology, especially when non-increased and/or physiologically high [18F]FDG uptake (as liver parenchyma) observed. We aimed to review the role of FAPIs primary metastatic lesions, and compare their performances with more "conventional" radiopharmaceuticals. A search algorithm based on terms "FAPI" AND ("hepatic" OR "liver") was applied, last update 1st January 2024. Out 177 articles retrieved, 76 studies reporting application FAPI at least one patient harboring or lesion(s) were fully analyzed. Although there some heterogeneity clinical conditions study methodology, showed an excellent performance common malignancies (hepatocarcinoma, intrahepatic cholangiocarcinoma) metastases (mostly from gastrointestinal tract lungs). higher tumor-to-background ratio for than found due lower background activity. Despite limited evidence, may be used assess suitability effectiveness FAPI-derived therapeutic agents such as [177Lu]Lu-FAPI. However, future prospective research wider population needed confirm performance.

Language: Английский

Citations

1